DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Turner NC, Telli ML, Rugo HS. et al.
Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2 mutations (ABRAZO).
J Clin Oncol 2017;
35 (Suppl.) Abstr.. 1007
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.